Avicanna (AVCNF) announced the publication of results from an investigator-led Medical Cannabis Real-World Evidence study conducted through the MyMedi.ca platform. The study led by Dr. Hance Clarke, Director of Pain Services at University Health Network, and has been published in the peer-reviewed Canadian Journal of Pain. The publication reports findings from a cohort of chronic pain patients enrolled in a prospective, observational study assessing patient-reported outcomes over a 24-week follow-up period. Outcomes were measured using validated assessment tools commonly employed in pain and mental health research. The observational results demonstrated statistically significant improvements from baseline in measures of pain interference and pain intensity, as well as improvements in validated measures of anxiety, depressive symptoms, and overall quality of life over the 24-week observation period.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVCNF:
- Avicanna Strengthens Board with Appointment of Capital Markets Veteran Michael Kott
- Avicanna director Paul Fornazzari resigns, Michael Kott appointed to board
- Avicanna Backs U.S. Cannabis Reclassification as It Advances 2025 Clinical and R&D Programs
- Avicanna ‘applauds’ executive order to reclassify cannabis